National insurer Aetna Inc. will promote use of the first generic version of Novartis AG’s blockbuster cancer drug Gleevec (imatinib) by requiring that patients try and fail on it first, before coverage of a branded alternative is approved, according to Aetna National Medical Director for Oncology Michael Kolodziej.
The requirement will apply to patients with chronic myeloid leukemia (CML) who are new to treatment. It will aim to discourage use of the newer and more expensive drugs in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?